An exclusive analysis of Covid-19 studies
More than 1,200 clinical trials aimed at testing treatment and prevention strategies against Covid-19 have been started since January. The speed and scale of the effort has been remarkable.
At the same time, a new STAT analysis shows that, taken as a whole, the effort has in many ways been disorganized and wasteful — with one in six trials focused on the malaria drugs hydroxychloroquine or chloroquine, which have shown no benefit in hospitalized patients.
At the same time, a new STAT analysis shows that, taken as a whole, the effort has in many ways been disorganized and wasteful — with one in six trials focused on the malaria drugs hydroxychloroquine or chloroquine, which have shown no benefit in hospitalized patients.
“If the goal was to optimize the likelihood of figuring out the best treatment options, the system is off course,” Robert Califf, a former FDA commissioner who now works at Verily, told STAT.
Many of the studies have been too small to offer any real insights into the virus, he said, and haven’t studied enough potential treatments. The analysis, conducted in partnership with AppliedXL, bears that out.
Many of the studies have been too small to offer any real insights into the virus, he said, and haven’t studied enough potential treatments. The analysis, conducted in partnership with AppliedXL, bears that out.
No hay comentarios:
Publicar un comentario